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Moscow State Medical University, Moscow, RussiaA B S T R A C TBackground: Diabetic foot ulcer (DFU) is considered to be one of the
most common and costly diabetic complications. The approach
unanimously recommended for patients with DFU is treatment by a
multidisciplinary foot care team, which in Russia mainly is limited to
few federal and regional hospitals. Currently, ﬁnancing schemes for
medical institutions are changing, thus raising the issue of setting
adequate tariffs. Objective: To identify the cost of treatment in the
specialized diabetic foot department and determinants of variation in
cost among individual patients with DFU in the Russian setting from
the perspective of a health care organization. Methods: We collected
data on treatment cost per admission to the Diabetic Foot Department
of the Endocrinology Scientiﬁc Center and information on patients’
characteristics derived from medical records. Data on costs were
analyzed, and descriptive statistics are reported. A standard multiple
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y of National Economy and Public Administratiotreatment cost for patients with DFU. Results: The mean treatment
cost was €3051. The mean cost of treatment for patients with DFU was
signiﬁcantly higher than that for diabetic patients without this
complication. The most relevant predictors of the costs of treatment
for patients with DFU were surgery provided and length of stay in
hospital. Conclusions: The cost for treatment of DFU by a multi-
disciplinary team in the federal medical institution was substantially
higher than basic medical insurance tariff for this disease. Because
revascularization procedures appeared to be the main cost driver, our
results stress the need for careful implementation of this type of
treatment for patients with DFU.
Keywords: cost drivers, cost of treatment, diabetic foot ulcer.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Diabetic foot ulcer (DFU) is considered to be one of the most
common and costly diabetic complications. It is suggested that
the lifelong incidence of foot ulcer for diabetic patients may reach
25% [1]. The prevalence of DFUs varies between 1.5% and 10% in
different populations [2]. According to the International Working
Group on the Diabetic Foot, patients with DFU consume 12% to
15% of the health care resources for diabetes. In a developing
country, this ﬁgure is expected to be even higher, up to 40% [2].
The World Health Organization estimated this proportion to be
around 15% to 25% [3]. Research conducted in the United States
showed that patients with DFU had $11,710 in incremental
annual health care costs for Medicare, and $16,883 for private
insurance, compared with matched patients with diabetes with-
out DFU. These results prove that DFU imposes a substantial
burden on public and private payers, ranging from $9 million to
$13 billion in addition to the costs associated with diabetes itself
(2012 US dollars) [4]. Kerr et al. [5] estimated the cost of diabeticfoot care in the period 2010 to 2011 at £580 million, almost 0.6% of
National Health Service expenditure in England [5].
More than half of the DFU episode treatment costs (reported
proportion ranged from 62% to 80.7%) were attributed to the
provision of inpatient care according to studies carried out in the
United States and Belgium and in a European multicenter study
[6–10]. This proportion is dependent on the severity of the DFU
episode and its outcome as was demonstrated by Apelqvist et al.
[11] in Sweden in 1990—the in-hospital stay contributed only 37%
of total costs in case of primary healing and 82% in case of
amputation [11].
Researchers from several countries consistently showed that
increase in severity of DFU is followed by the enormous growth in
cost. The total treatment cost of superﬁcial ulcer was 5 times
lower than the treatment cost of abscess/osteitis and 10 times
lower than the treatment cost of gangrene in the above-
mentioned Swedish study [11]. The same trend, even with a
more pronounced difference, was observed in the US-based
study, conducted in the period 2000 to 2001, in which the costociety for Pharmacoeconomics and Outcomes Research (ISPOR).
echnology Assessment, Institution of Applied Economics, Russian
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(gangrene or amputation) [6]. The total direct cost for patients
with DFU in the group of patients with the most severe disease
(combination of infection and peripherial arterial disease [PAD])
was almost 4 times higher than that for patients with the least
severe disease (no infection or PAD) in the prospective multi-
center study with 14 participating DFU treatment centers from 10
European Union countries (Eurodiale) [10].
The most feared outcome of DFU is amputation, which leads
to permanent disability, loss of mobility, and signiﬁcant decrease
in the quality of life [12–14].
Many new treatments and strategies, aimed at decreasing the
time to healing of DFU and, consequently, the rate of amputa-
tions, appeared during recent decades. Evidence of their effec-
tiveness, however, is often insufﬁcient to recommend their
adoption in routine practice [15,16]. Treatment of patients with
DFU by multidisciplinary foot care teams, who are able to address
critical healing issues for DFU, such as glycemic control, infec-
tion, off-loading of high plantar surface pressures, restoration of
lower-extremity blood supply, and local wound care, appears to
be one of the main recommendations unanimously given by
national and international guidelines [2,16–18].
Most of the studies on DFU epidemiology and related costs
come from the industrialized countries, whereas studies from
the former Soviet Union and Eastern European countries are
extremely rare.
The prevalence of DFU among registered diabetic patients in
Russia varies between 2.2% and 8.5% [19–21]. The annual rate of
amputations related to DFU is estimated to be between 6.7 and
8.9 per 1000 diabetic patients [22]. The proportion of above-ankle
amputations is higher in Russia than the one reported in
industrialized countries and reaches 45% to 47% of all DFU-
related amputations [10,23]. Although the existing Russian guide-
lines on the treatment of diabetic foot conform to the interna-
tional standards, practitioners point out that the level of care that
patients with DFU receive in Russia is far from it, mainly because
of inadequate organization and ﬁnancing [23,24].
The outpatient care to patients with DFU in Russia in most of
the cases is provided by general surgeons, but the network of
outpatient diabetic foot care clinics is also expanding and now
there are almost 200 ofﬁces in Russia. The inpatient care is
provided in the municipal hospitals, mainly in the general
surgery departments for patients with infected wounds. All these
services are paid through the system of public medical insurance,
according to the reimbursement rates, which are different for
every Russian region.
The provision of the recommended complex treatment for
patients with DFU by multidisciplinary foot care teams is limited
mostly to the few federal and regional hospitals. For several
years, access to these hospitals for patients with DFU was
ensured by the state program “Provision of highly technological
medical care” (HTMC). The HTMC program, annually approved by
the Russian government, speciﬁed the covered diseases, types of
treatment, reimbursement rates, as well as the planned number
of admissions to specialized medical centers. More than 30% of
the planned HTMC admissions of the “Endocrinology” proﬁle (the
category that includes patients with DFU) were allocated to the
Endocrinology Scientiﬁc Center (ESC) in Moscow [25]. Currently,
the HTMC program is gradually transferred into the public
medical insurance system, raising the issue of adequate pricing
for these treatments to ensure access to them for the general
population.
Therefore, our objective was to identify the cost of treatment
in the specialized diabetic foot department and determinants
of variation in cost among individual patients with DFU in
the Russian setting from the perspective of a health care
organization.Methods
We collected data on all admissions to the ESC Diabetic Foot
Department reimbursed by the federal budget through the HTMC
program in 2011.
Data on individual patient treatment cost were obtained from
ESC’s Economic Department database, where it was presented as
total cost per admission. It included costs of medical procedures
and medications provided, as well as the cost of staying in the
hospital (“hotel services”). All costs were retrospectively calcu-
lated using the data on consumption derived from individual
patients’ medical records and internal ESC’s prices. Internal price
per procedure was deﬁned following the World Health Organiza-
tion recommendations and included labor costs, cost of consum-
ables, which type and amount did not depend on individual
patient’s characteristics, equipment depreciation, and overhead
costs [26] (Personal communication with an employee of the
ESC’s Economic Department, responsible for calculating the costs
data and maintaining the costs database, March 3, 2014). The
amount of labor and consumables required per procedure was
assessed by ESC’s Economic Department employees using expert
opinion. Labor costs were calculated on the basis of standard
salary of the specialist executing the procedure. The medications’
and consumables’ costs were estimated using the procurement
prices for the institution. In case the procedure required using
consumables, the type or quantity was dependent on individual
patient’s characteristics (e.g., balloon catheters or stents); their
costs were calculated individually and added to the price of the
procedure. The price per day in hospital (“hotel services”) was
retrospectively based on annual hospital’s expenditures on
hospital facilities and number of hospital days provided (Per-
sonal communication with an employee of the ESC’s Economic
Department, responsible for calculating the costs data and
maintaining the costs database, March 3, 2014). Some of the
prices used for calculating treatment cost are presented in
Table 1.
Costs in Russian rubles were converted into euros using the
average annual exchange rate for year 2011 (€1 ¼ 40.8848 Russian
rubles).
Besides data on treatment costs for individual patients, we
have collected information from their medical records on full
diagnosis, including the presence of PAD, severity of disease
according to Wagner classiﬁcation (clinical classiﬁcation of the
severity of the lesion, where grade 1 is superﬁcial ulcer; grade 2—
deep ulcer with no bone involvement; grade 3—osteitis, abscess,
or osteomyelitis; and grade 4—local gangrene) and provision of
renal dialysis and surgery.
All admissions were analyzed as separate cases, although
some patients had more than one admission during the year. Our
decision was determined by the objective of our research—to
deﬁne cost drivers for the individual hospitalization, not the total
process of treatment of a patient. Other patients in the case of
severe DFU may also have more than one admission during the
year but to different hospitals; therefore, this information was
unavailable for the analysis.
We identiﬁed three main reasons for the admissions: 1)
DFU; 2) Charcot foot or history of foot ulcers; this group was
considered as requiring treatment for the prevention of ulcer-
ation in future; and 3) severely decompensated diabetes with
sensory neuropathy and PAD, but without the history of previous
ulceration. We studied costs for all three groups. Because the
number of observations for each reason of admission was quite
small and the treatment costs were skewed to the right (Shapiro-
Wilk test was signiﬁcant proving the non-normal distribution
of data), we used bootstrapping (1000 replications) to examine
the variation in costs in the three groups. The non-normal
Table 1 – Procedure and consumable prices used for
calculations of the treatment costs (in euro), 2011.
Cost item Price
per service (€)
Stay in the hospital (price per day, only
“hotel services”)
16.88
Clinical blood analysis (price per service) 7.51
Measurement of the blood glucose 1.98
Angiography of the lower extremities 201.71
X-ray of the foot 21.55
Duplex scan of low-extremity vessels 20.57
Transcutaneous oximetry (1 point) 10.66
Dressing the purulent wounds 13.01
Application of the contact cast 20.86
Debridement of the wound or infected
tissues, removal of necrosed tissue*
896.89
Debridement (removing of necrosed tissue),
using the hydrosurgery system Versajet
788.48
Skin grafting 727.97
Drain of abscess or phlegmon 409.74
Hemodialysis 113.39
Debridement, removal of affected bone 561.31
Disarticluation 525.92
Lower-extremity amputation 905.52
Balloon angioplasty of the peripherial
arteries
357.98
Balloon catheter (1 item)† €394.0–€972.0
Dressing material (1 pack)† 0.45–0.96
Materials for total contact casting (1 pack)† 8.0–14.0
Antibiotics (cost per day of treatment)† 3.0–45.0
* Price for surgery procedure includes the price for all anesthesiol-
ogy procedures.
† Minimal and maximal prices for the category are provided. Total
costs of treatment for every admission were calculated using the
price of particular medication (dressing, etc.) and amount con-
sumed on the basis of medical records.
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Mann-Whitney U test to evaluate the statistical signiﬁcance of
the observed differences in the treatment costs among groups
with different reasons for admission. The same methods were
also applied to study in detail the treatment costs for patients
with present ulcers depending on the severity of lesions. Because
in total we were testing ﬁve comparisons on one data set, a
Bonferroni-adjusted signiﬁcance level of 0.01 was calculated to
account for the increased possibility of type I error.
A standard multiple regression analysis was performed to
identify the main drivers of treatment costs for the group of
patients with DFU. Because the costs were right-skewed, a
standard log transformation was applied. Sex, type of diabetes,
renal dialysis, length of stay in a hospital, presence of PAD, type
of surgery provided during the admission, and severity of DFU
were included into the analysis as independent variables. Cate-
gorical variables were coded with 1 for patients in whom a
condition was present and with 0 for absence. Severe DFU was
deﬁned as Wagner grade 3 or 4, and grades 1 or 2 were considered
as nonsevere ulceration. P o 0.05 was considered statistically
signiﬁcant. The normality of residuals distribution was assessed
by means of normal Q-Q plot of standardized residuals.
All statistical analyses were performed in IBM SPSS
Statistics, version 21, and bootstrapping in Microsoft Excel 2011
for Mac.Results
The Collected Data Set
There were 194 hospital admissions of 174 patients to the
diabetic foot department in the frames of the HTMC program
during 2011. Multiple hospital admissions were observed for 17
patients (14 patients had two admissions and 3 patients had
three admissions). Most of the multiple admission cases (12 of 17)
were due to the treatment of the same ulcer episode; the other
reason for multiple admissions was revascularization procedures
on both extremities.
Patients had DFUs in 122 admissions, and 48% of the cases
were severe, that is, Wagner grades 3 (deep ulcer with osteomye-
litis, or abscess) and 4 (gangrene of toes or forefoot). Skin was
intact in 48 admissions, but patients had Charcot foot or history
of previous ulceration. The provided treatment was mainly
aimed at the prevention of future ulcer episodes (i.e., conserva-
tive treatment in the case of decompensated diabetes, revascula-
rization, or orthopedic surgery). The last 24 admissions (12%) in
the collected data set were for the provision of treatment to
patients with severely decompensated diabetes, neuropathy, and
PAD, but without the history of previous foot ulcers. All patients
had multiple diabetes complications, and renal dialysis was
required during 14 admissions. Surgery was provided during the
104 admissions and in 10 cases patients received foot and
vascular surgery during the same admission. The description of
the collected data set is presented in Table 2.Treatment Costs
The mean treatment cost in the diabetic foot department was
€3051. The median cost was substantially lower (€1779) because
the costs were skewed to the right. The interquartile range (IQR)
was €1191 to €3587.
The mean treatment cost for patients with DFU was €3668
(median €2531; IQR €1487–€4788), and the individual costs varied
from €876 to €15,734. The mean and median cost for the group of
patients with a history of DFU was lower—€2423 and €1431,
respectively; accordingly, the IQR was €1120 to €2464. The
minimal cost in this group was €733 and maximal €12,318. The
lowest mean treatment cost was observed for patients without a
history of ulceration: €1166 (median €1124; IQR €876–€1410). This
group also has the lowest variation in individual costs: €718 to
€2068. The difference between raw and bootstrapped estimates of
treatment costs for groups with different reasons for admission
was quite low (Table 3).
A Mann-Whitney 2-tailed U test showed that treatment costs
for patients with DFU and patients with Charcot foot or a history
of DFU differed signiﬁcantly (U ¼ 1751.5; Z ¼ –4.073; P o 0.001,
Bonferroni-adjusted signiﬁcance level ¼ 0.01). Also, the difference
in costs for patients with a history of DFU and intact skin and
diabetes patients without this complication was also statistically
signiﬁcant (U ¼ 329.5; Z ¼ –2.949; P ¼ 0.003, Bonferroni-adjusted
signiﬁcance level ¼ 0.01).
The cost of treatment for patients with DFU grew with the
severity of disease. The difference between mean treatment costs
for grades 1 and 2 was less pronounced than the difference
between grades 2 and 3 and between grades 3 and 4 (Table 3).
The treatment cost for patients with DFU with Wagner grade 2
was signiﬁcantly different from the cost for the group with
Wagner grade 3 (U ¼ 387; Z ¼ –2.581; P ¼ 0.010; Bonferroni-
adjusted signiﬁcance level 0.01). The difference between grades 1
and 2 was not statistically signiﬁcant, as well as the difference
between grades 3 and 4.
Table 2 – Characteristics of the collected data set.
Characteristic Patients with severely
decompensated DM,
neuropathy, and PAD,
no history of DFU
Patients with Charcot





No. of hospital admissions 24 48 122 194
No. of patients 24 46 104 174
Sex: male, n (%) 11 (46)* 20 (42) 58 (48) 89 (46)
Insulin-independent diabetes, n (%) 16 (67) 30 (63) 97 (80) 143 (74)
PAD present, n (%) 0 21 (44) 63 (52) 84 (43)
Renal dialysis, n (%) 0 0 14 (11) 14 (7)
Revascularization provided, (%) 0 9 (20) 28 (23) 37 (19)
Foot surgery provided, n (%) 0 6 (13) 41 (34) 57 (29)
Both types of surgery provided during one
admission, n (%)
0 0 10 (8) 10 (5)
Wagner grade 1–2, n (%) NA NA 64 (52) 64 (33)
Wagner grade 3–4, n (%) NA NA 58 (48) 58 (30)
DM, diabetes mellitus; DFU, diabetic foot ulcer; NA, not applicable/available; PAD, peripherial arterial disease.
* Data are presented as a number of cases (% of all admissions in the group).
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Sex, type of diabetes, renal dialysis, presence of PAD, type of
surgery provided, length of hospital stay, and severity of DFU
were used in a standard regression analysis to predict the log-
transformed treatment cost. The regression model accounted for
approximately 66% of the variance in log-transformed admission
cost (R2 ¼ 0.659; adjusted R2 ¼ 0.635). The statistical signiﬁcance
of the model was tested with analysis of variance, F(8,113) ¼
27.29, P o 0.001, and the plot of observed log-transformed costs
against predicted values is mostly located along the regression
line, thus also suggesting the good ﬁt of the model. Standardized
residuals mostly lie on the line on the Q-Q plot; therefore, we
consider that there was no violation of the assumption of the
normally distributed results (Fig. 1).
The raw and standardized regression coefﬁcients together
with correlation coefﬁcients and P values for the t test are
presented in Table 4. We have also performed the regression
analysis with backward elimination, but we did not observe any
substantial differences (results not shown).Table 3 – Raw and bootstrapped estimates of the treatme
(in euro).
Reason for admission Mean Media
Raw Bootstrapped* Raw Boo
All admissions 3051 3047 1779
Severely decompensated
diabetes, no history of
DFU
1166 1165 1124




DFU, all patients 3668 3667 2531
DFU, Wagner grade 1 2450 2466 1555
DFU, Wagner grade 2 2821 2821 1858
DFU, Wagner grade 3 3937 3930 3568
DFU, Wagner grade 4 5340 5337 4126
DFU, diabetic foot ulcer.
* 1000 replications.Of all the predictors in the model, only length of stay and
provided surgery were statistically signiﬁcant. Thus, the severity
of DFU, which correlated rather substantially with log-
transformed costs (r ¼ 0.42), even stronger than foot surgery
(r ¼ 0.38), in combination with the other predictors was not
signiﬁcant in the multiple regression model. The predictive role
of the severity of DFU in the model was accomplished by other
variables in the analysis.
The raw regression coefﬁcient (B) predicts changes in the
dependent variable for every unit increase of that predictor. The
standardized regression coefﬁcient (β) predicts the change in the
dependent variable measured in SDs for 1 SD change in predic-
tor’s value. Therefore, the comparability of coefﬁcients is
achieved. In our analysis, even though changes in the length of
stay in the hospital by 1 unit had a smaller effect on the pre-
dicted cost than did provision of foot surgery (B ¼ 0.02 vs
B ¼ 0.40), contribution of the length of stay to the model was gre-
ater (β ¼ 0.32 vs. β ¼ 0.28, respectively). The highest values of
regression coefﬁcients were found for vascular surgery (B ¼ 0.91;
β ¼ 0.59).nt cost depending on the reason for admission
n 5th percentile 95th percentile
tstrapped* Raw Bootstrapped* Raw Bootstrapped*
1771 876 890 9,602 9,183
1107 758 839 1,970 1,686
1419 828 868 9,079 7,888
2640 1030 1056 11,173 10,120
1610 876 999 12,892 6,766
1862 996 1035 7,534 7,270
3539 1078 1287 10,748 8,091
4220 1407 1650 12,826 11,602
Fig. 1 – Results of the regression analysis with all independent variables entered.
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variance uniquely explained by each predictor. We found that
vascular surgery uniquely accounted for about 18% of the var-
iance in log-transformed costs, length of stay in the hospital for
6%, and foot surgery for 4%.
Taking into account counterintuitive results of the regres-
sion analysis with all variables, when severity was not
signiﬁcant, and presence of dialysis and PAD had negative
coefﬁcients, implying reduction in costs, we carried out
additional regression analysis, including only independent
variables, whose values could be known at the moment ofTable 4 – Results of the multivariate regression analysis
patients.
Variables B Stan
Regression analysis 1 (R2 ¼ .659, Adjusted R2 ¼ .635)
Intercept 7.014
Length of hospital stay .020
Foot surgery (0 – no, 1 – yes) .402
Vascular surgery (0 – no, 1 – yes) .911
Dialysis (0- no, 1 – yes)  .024 
PAD present (0- no, 1 – yes)  .021 
Severe DFU (Wagner grade 3-4, 0- no, 1 – yes) .120
Gender (1 – male, 0 – female)  .070 
Type of diabetes (0 – non-insulin dependent, 1-
insulin dependent)
.090
Regression analysis 2, only predictors known at admission included (R2
Intercept 7.504
Dialysis (0- no, 1 – yes) .062
PAD present (0- no, 1 – yes) .472
Severe DFU (Wagner grade 3-4, 0- no, 1 – yes) .492
Gender (1 – male, 0 – female)  .130 
Type of diabetes (0 – non-insulin dependent, 1-
insulin dependent)
.054admission. Our aim was to create a model that could predict
cost on the basis of patients’ characteristics, not the
amount of services provided. This model accounted only
for 29% of the variance in log-transformed admission cost
(R2 ¼ 0.290; adjusted R2 ¼ 0.259; F[5,116] ¼ 9.48; P o 0.001).
Severity of disease (grades 3 and 4 according to Wagner
classiﬁcation) was the most relevant explanatory variable in
the model followed by the presence of PAD. Other variables
had a relatively low weight in the model, and difference in
costs explained by them was not statistically signiﬁcant. The










.324 .573 .256 o.001
.277 .378 .201 o.001
.589 .564 .419 o.001
.011 .217  .009 .866
.014 .389  .011 .846
.083 .418 .065 .238
.049  .11 .048 .388
.051 .074 .047 .390
¼ .290, Adjusted R2 ¼ .259)
o.001
.028 .217 .025 .754
.330 .389 .320 o.001
.343 .418 .321 o.001
.091  .111  .091 .250
.031 .074 .029 .712
V A L U E I N H E A L T H R E G I O N A L I S S U E S 7 C ( 2 0 1 5 ) 8 0 – 8 6 85Discussion
We have shown that the bootstrapped mean cost of inpatient
treatment in the Diabetic Foot Department in the ESC in 2011 was
€3057 (median €1795). These values are lower than those
obtained in preliminary analysis, limited to the descriptive
statistics and performed on the marginally different data set (in
some cases, costs for multiple hospitalizations during the year
were combined and patients without diabetic foot syndrome
were excluded): €3605 (median €2200) [27]. In 2014, the basic
public medical insurance tariff for disease-related group,
which included DFU, was set at €643, substantially lower than
our value.
The cost of treatment for patients with DFUs was 3.2 times
higher than that for diabetic patients who did not suffer from this
complication. The difference was statistically signiﬁcant. These
ﬁndings correspond to the results demonstrated by Rice et al. [4],
though in that research total costs, including inpatient and
outpatient care, were compared.
The trend of the growth in treatment costs correspondingly to
the severity of the DFU, previously described by other researchers
[6,10,11], was also observed in the present study. The mean cost
for patients with the highest observed grade of DFU according to
the Wagner classiﬁcation was almost 2 times higher than that for
patients with the lowest grade. We did not ﬁnd a strong relation-
ship, however, between disease severity and the total cost of
treatment in the regression analysis. In additional analysis, when
“secondary” variables, representing the amount of services pro-
vided, were excluded, severity and presence of PAD were statisti-
cally signiﬁcant predictors.
The performed regression analysis demonstrated that surgery
provided and length of stay in the hospital were the main
determinants of treatment costs, similar to international ﬁnd-
ings. Ragnarson Tennvall et al. [28] analyzed the total costs of
treatment of the diabetic patient with deep foot infection,
including inpatient and outpatient care, topical and antibacterial
treatment, and orthopedic appliances, and found the surgery
provided to be one of the most important cost-driving factors, as
well as the duration of wound healing. In a recently published
US-based study, aimed at analyzing inpatient DFU cost changes
over time, the main factors contributing to the escalating cost per
patient hospitalization included revascularization procedures,
minor amputations, and increased patient comorbidities, based
on multivariable analysis [29].
The fact that we have obtained data for analysis only from
one medical institution limits the generalization of results of our
study. As far as we know, standardized prices for medical
resources do not exist in Russia so far. Besides, because the
process of determining the institutional internal prices was
described to us during the personal communication, it is difﬁcult
to disclose it in full detail. We can assume, however, that we had
information on the substantial part of hospital admissions of
patients with DFU in the frames of the HTMC program because
the ESC provides almost 30% of the planned hospitalizations for
the “Endocrinology” category, which covers patients with DFU. To
explore the variation in costs, we used bootstrapping analysis; of
course, the small sample size inﬂuenced this estimate.
A limitation of the data that were made available to us was
their aggregation to total costs without a breakdown reﬂecting the
number of procedures provided and the price per procedure as
reported in Table 1. Consequently, it was impossible to perform
deterministic sensitivity analyses on prices of services. Multiple
admissions potentially could also be a cost-driving factor, but we
did not include them into regression analysis because there was no
information available about possible admissions to other hospitals.
The use of log-transformed costs as the dependent variable in theregression analysis also limits the generalizability of the results
and requires accurate interpretation.
The information on the cost of DFU treatment in Russia is scarce,
and the present study provides only a small piece of information.
Our results, however, could be used as evidence for setting adequate
tariffs for this type of treatment in the public health insurance or as
the basis for further cost-effectiveness research.Conclusions
The mean cost of treatment in the specialized diabetic foot
department in the Russian setting in 2011 exceeded €3000, almost
5 times higher than the corresponding tariff in the public health
insurance system. Costs for patients with DFU were signiﬁcantly
higher than costs for patients without this complication. The
surgery provided, especially revascularization procedures, and
length of stay were the main predictors of the variation in costs
for patients with foot ulcers.
The costs for treatment of DFU by a multidisciplinary team in
the federal medical institution are high and may become a disas-
trous economic burden for patients without ample public ﬁnancing.
However, the costs are substantially driven by the vascular surgery
provided; therefore, our results stress the need for careful imple-
mentation of this type of treatment for patients with DFU.
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